Susan Rasmussen
Family · Moberly, MONPI 1215933544
Payments from drug & device makers
Across 224 payments — averaging $16.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$705
- AbbVie$601
- Lilly USA, LLC$584
- Novo Nordisk$333
- Amgen$186
- Takeda Pharmaceuticals U.S.A., Inc.$160
- plus $1K from 31 others
What the payments were for
- Food & beverage$3,664100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 33 | $705 |
| AbbVie(2 entities) | 39 | $601 |
| Lilly USA, LLC | 43 | $584 |
| Novo Nordisk | 25 | $333 |
| Amgen | 11 | $186 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $160 |
| Otsuka America Pharmaceutical, Inc. | 4 | $81 |
| Pfizer | 5 | $80 |
| Nestle Healthcare Nutrition Inc. | 4 | $79 |
| Dexcom, Inc. | 4 | $73 |
| Sumitomo Pharma America, Inc. | 5 | $66 |
| GSK | 3 | $56 |
| Boehringer Ingelheim | 3 | $52 |
| Exact Sciences | 3 | $49 |
| Viatris Specialty LLC | 2 | $43 |
| Merck | 3 | $40 |
| Lundbeck LLC | 2 | $34 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $34 |
| Bayer | 2 | $32 |
| Sobi, Inc | 2 | $32 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $31 |
| Amarin Pharma, Inc. | 2 | $29 |
| Biohaven Pharmaceuticals, Inc. | 2 | $28 |
| Vertex | 1 | $27 |
| Verona Pharma, Inc. | 1 | $24 |
| Teva Pharmaceuticals USA, Inc. | 1 | $23 |
| Esperion Therapeutics, Inc. | 1 | $22 |
| Neurocrine Biosciences, Inc. | 1 | $19 |
| Johnson & Johnson | 1 | $18 |
| Grifols USA, LLC | 1 | $18 |
| Aimmune Therapeutics, Inc. | 1 | $18 |
| Axsome Therapeutics, Inc. | 1 | $17 |
| Ardelyx, Inc. | 1 | $17 |
| Novartis | 1 | $16 |
| Ultragenyx Pharmaceutical Inc. | 1 | $14 |
| Phathom Pharmaceuticals, Inc. | 1 | $13 |
| Eisai Inc. | 1 | $12 |
How this compares
$3,664 in reported general payments places this provider in the 85th percentile of 3,812 family providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 50 | $48,482 |
| EliquisApixaban | 43 | $42,078 |
| OzempicSemaglutide | 35 | $37,247 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 32 | $26,857 |
| TrulicityDulaglutide | 18 | $24,472 |
| MounjaroTirzepatide | 17 | $20,782 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 28 | $20,106 |
| JanuviaSitagliptin Phosphate | 18 | $19,133 |
| Tresiba Flextouch U-100Insulin Degludec | 14 | $14,862 |
| Tresiba Flextouch U-200Insulin Degludec | 23 | $12,889 |
| Breo ElliptaFluticasone/Vilanterol | 24 | $12,482 |
| RybelsusSemaglutide | 11 | $10,715 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 17 | $6,899 |
| Spiriva HandihalerTiotropium Bromide | 13 | $6,699 |
| Incruse ElliptaUmeclidinium Bromide | 12 | $4,396 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $52 | $48,48250 claims |
| Novo NordiskOzempic, Rybelsus | $333 | $47,96346 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Arexvy | $56 | $47,61982 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $584 | $45,25435 claims |
| PfizerEliquis | $80 | $42,07843 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $705 | $22,85140 claims |
| MerckJanuvia | $40 | $19,13318 claims |
| AbbVieSynthroid | $601 | $1,32226 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,812 family providers in Missouri.
Other family in Moberly
- Connie SpencerSaint Joseph$320K
- Shayla SandersKansas City$306K
- Tamera WolfLees Summit$215K
- Tiffany ArnoldFestus$177K
- Tiffany NelsonSedalia$164K
- Chelsey BeckerSaint Peters$104K
- Carey PattonDes Peres$94K
- Marcy MarkesColumbia$92K
- Laura HedigerSpringfield$71K
- Rebecca SeabaughSaint Louis$68K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.